Empowered Patient Podcast

Amy Brown, CEO of Authenticx, uses conversational intelligence to analyze conversations between humans and between humans and chatbots to gain insights that can drive improvements in patient experience, operational efficiency, and faster resolution of problems in the healthcare environment. Using AI and trained professionals, the Authenticx solution can help pharmaceutical companies improve drug launches, personalize customer interactions and respond more effectively to patient needs. In clinical situations, the machine learning models help identify and address obstacles impeding more robust patient/provider/payer relationships.

Amy explains, "At Authenticx, we really target bidirectional conversations. We can take in all types of unstructured data that exist: notes, social, etc. That said, we find the most insightful and contextually rich types of data sources are the ones that represent a back-and-forth between customer and company. And in our world, we're working with very large healthcare companies, like pharmaceutical manufacturers, health insurance companies, health and hospital systems."

"They're typically having conversations with patients or caregivers, any type of healthcare consumer, they're also having conversations with other stakeholders in the healthcare system, like insurance companies talking to providers' offices, or doctors' offices talking to pharmaceutical manufacturers. We find that the research and study of that back-and-forth bidirectional communication, and doing that at scale, is incredibly insightful to the business."

"We ingest the call recordings or the chat interaction files into our platform, and we apply AI to listen for the things that matter most to healthcare companies. We've spent five years curating our own proprietary training data, where we have listeners, human listeners, who have listened to hundreds of thousands of conversations. We intentionally hired social workers, healthcare workers, nurses, people who have worked inside the healthcare system, because we found that interpreting the communication they're listening to is so crucially important to making high-quality AI."

#Authenticx #ListeningWithAI #ConversationalIntelligence #PatientExperience #AIinHealthcare

Authenticx.com

Listen to the podcast here

Amy Brown, CEO of Authenticx, uses conversational intelligence to analyze conversations between humans and between humans and chatbots to gain insights that can drive improvements in patient experience, operational efficiency, and faster resolution of problems in the healthcare environment. Using AI and trained professionals, the Authenticx solution helps pharmaceutical companies improve drug launches, personalize customer interactions and respond more effectively to patient needs. In clinical situations, the machine learning models help identify and address obstacles impeding more effective patient/provider/payer relationships.

Amy explains, "At Authenticx, we really target bidirectional conversations. We can take in all types of unstructured data that exist: notes, social, etc. That said, we find the most insightful and contextually rich types of data sources are the ones that represent a back-and-forth between customer and company. And in our world, we're working with very large healthcare companies, like pharmaceutical manufacturers, health insurance companies, health and hospital systems."

"They're typically having conversations with patients or caregivers, any type of healthcare consumer, they're also having conversations with other stakeholders in the healthcare system, like insurance companies talking to providers' offices, or doctors' offices talking to pharmaceutical manufacturers. We find that the research and study of that back-and-forth bidirectional communication, and doing that at scale, is incredibly insightful to the business."

"We ingest the call recordings or the chat interaction files into our platform, and we apply AI to listen for the things that matter most to healthcare companies. We've spent five years curating our own proprietary training data, where we have listeners, human listeners, who have listened to hundreds of thousands of conversations. We intentionally hired social workers, healthcare workers, nurses, people who have worked inside the healthcare system, because we found that interpreting the communication they're listening to is so crucially important to making high-quality AI."

#Authenticx #ListeningWithAI #ConversationalIntelligence #PatientExperience #AIinHealthcare

Authenticx.com

Download the transcript here

Dr. Marc Conant, Chief Medical Officer at Addimmune, has been working on HIV/AIDS for over 40 years and highlights the progress that has been made in developing effective HIV drugs. The mission at Addimmune is to develop a functional cure for HIV by modifying the patient's cells to enhance the immune system's ability to control the virus. This autologous cell therapy approach has been used successfully in treating leukemia and lymphoma and shows promise in suppressing HIV.

Marc explains, "I started caring for AIDS patients in 1981, and it wasn't until AGT came along in 1988, '87, '88, that we even had anything that would work. Up until that time, everyone who contracted the disease died. HIV kills about 94% of people who are infected. What we saw early on with AGT was a drug that suppressed the virus, and then we found the next drug that suppressed the virus, and then the next one, and now we have close to 40 different drugs that can suppress the virus."

"Now, there's been even a step beyond that. You all probably see on your television every night injections that can be given once every two months, and sure enough, that works and works great, so instead of taking a pill every day, you only need to see a doctor six times a year. Every two months, you go in for two injections, and you're good for two months. And compliance is better. Patients remember to take their drug because it's given to them in an injection."

"All of that, though, still requires putting in a drug. We're hoping to take the patient's cells, modify them, put them back in the patient, and have a one-and-done treatment for the rest of his life with these modified cells, which helps the patient's immune system control the virus. The virus will be suppressed. The patient will not need to take more medication. The patient will not have side effects. The patient doesn't have to remember to take his drugs, and we've got a functional cure that will control the disease."

#Addimmune #HIV #AIDS #HIVAIDS #CARTCell #CellTherapy #FunctionalCure #HIVTreatment #AutologousCellTherapy

Addimmune.com

Listen to the podcast here

Dr. Marc Conant, Chief Medical Officer at Addimmune, has been working on HIV/AIDS for over 40 years and highlights the progress that has been made in developing effective HIV drugs. The mission at Addimmune is to develop a functional cure for HIV by modifying the patient's cells to enhance the immune system's ability to control the virus. This autologous cell therapy approach has been used successfully in treating leukemia and lymphoma and shows promise in suppressing HIV.

Marc explains, "I started caring for AIDS patients in 1981, and it wasn't until AGT came along in 1988, '87, '88, that we even had anything that would work. Up until that time, everyone who contracted the disease died. HIV kills about 94% of people who are infected. What we saw early on with AGT was a drug that suppressed the virus, and then we found the next drug that suppressed the virus, and then the next one, and now we have close to 40 different drugs that can suppress the virus."

"Now, there's been even a step beyond that. You all probably see on your television every night injections that can be given once every two months, and sure enough, that works and works great, so instead of taking a pill every day, you only need to see a doctor six times a year. Every two months, you go in for two injections, and you're good for two months. And compliance is better. Patients remember to take their drug because it's given to them in an injection."

"All of that, though, still requires putting in a drug. We're hoping to take the patient's cells, modify them, put them back in the patient, and have a one-and-done treatment for the rest of his life with these modified cells, which helps the patient's immune system control the virus. The virus will be suppressed. The patient will not need to take more medication. The patient will not have side effects. The patient doesn't have to remember to take his drugs, and we've got a functional cure that will control the disease."

#Addimmune #HIV #AIDS #HIVAIDS #CARTCell #CellTherapy #FunctionalCure #HIVTreatment #AutologousCellTherapy

Addimmune.com

Download the transcript here

Dr. John Showalter, Chief Product Officer of Linus Health, shines a light on the current methods of measuring cognitive health and emphasizes the need for a more holistic approach to assessing brain health. Linus works on digital cognitive assessment tools and AI models to detect cognitive impairment and early warning signs of Alzheimer's and other dementias. These tools also consider anxiety, sleep patterns, and lifestyle factors and support personalized care plans for patients and their caregivers.

John elaborates, "Right now, we have this performance-based understanding of cognitive processing and brain health. And I'm not sure that is the best way for us to be looking at brain health because, to me, as a primary care physician and someone who's very much into a more holistic view of the individual, brain health should be much more about your ability to achieve what you want to achieve, interact with the people that you want to interact with and have a higher quality of life. But there's not a real good definition of that."

"One of the classic tests that your primary care physician would use was called the Mini Cog. It's when you were asked to remember three words, draw a clock, and then, after drawing that clock, repeat the words that you were given. We have taken that and put it on an iPad with an iPad pencil. We now analyze not only whether or not you remember the words but the pattern of speech when you said the words, the pauses, and the intonation of your speech when you were repeating the words back."

"We also have multiple clock drawings, and because of the immense amount of sensors in the iPad and the iPad pencil, we're able to look at hundreds of features captured at 120 times a second and put them through machine learning models to understand how well an individual's brain is functioning. Then that translates very accurately to understanding if they meet the clinical diagnosis for cognitive impairment or the clinical diagnosis for dementia, understanding possible functional challenges."

@LinusHealth #LinusHealth @JohnShowalterMD #CognitiveHealth #BrainHealth #Cognition #CognitiveDecline

linushealth.com

Listen to the podcast here

Dr. John Showalter, Chief Product Officer of Linus Health, shines a light on the current methods of measuring cognitive health and emphasizes the need for a more holistic approach to assessing brain health. Linus works on digital cognitive assessment tools and AI models to detect cognitive impairment and early warning signs of Alzheimer's and other dementias. These tools also consider anxiety, sleep patterns, and lifestyle factors and support personalized care plans for patients and their caregivers.

John elaborates, "Right now, we have this performance-based understanding of cognitive processing and brain health. And I'm not sure that is the best way for us to be looking at brain health because, to me, as a primary care physician and someone who's very much into a more holistic view of the individual, brain health should be much more about your ability to achieve what you want to achieve, interact with the people that you want to interact with and have a higher quality of life. But there's not a real good definition of that."

"One of the classic tests that your primary care physician would use was called the Mini Cog. It's when you were asked to remember three words, draw a clock, and then, after drawing that clock, repeat the words that you were given. We have taken that and put it on an iPad with an iPad pencil. We now analyze not only whether or not you remember the words but the pattern of speech when you said the words, the pauses, and the intonation of your speech when you were repeating the words back."

"We also have multiple clock drawings, and because of the immense amount of sensors in the iPad and the iPad pencil, we're able to look at hundreds of features captured at 120 times a second and put them through machine learning models to understand how well an individual's brain is functioning. Then that translates very accurately to understanding if they meet the clinical diagnosis for cognitive impairment or the clinical diagnosis for dementia, understanding possible functional challenges."

@LinusHealth #LinusHealth @JohnShowalterMD #CognitiveHealth #BrainHealth #Cognition #CognitiveDecline

linushealth.com

Download the transcript here

Ha Tran, Medical Head, Cell and Gene Therapy at Astellas Pharma is developing gene therapy approaches to fight neuromuscular diseases, central nervous system disorders, and ophthalmology conditions. There is strong evidence that this approach can be a way to treat and possibly cure rare diseases. Ha explains the challenges of running gene therapy trials for rare diseases and the unique patient journey required to run a successful trial.

Ha explains, "Currently, at Astellas, our platform is AAV gene therapy, which is a replacement. Additionally, in our early pipeline, we are looking at both gene therapy replacement and vectorized RNA knockdown. We also have a cell therapy division, which I also cover. For that, we're looking at in vivo cell therapy."

"Honestly speaking, gene and cell therapy trials have their nuances since they are often a single infusion or single injection. So, the preclinical data packages and long-term follow-up plans differ from standard drug development. But the biggest nuances actually for clinical trial design are in rare diseases. The FDA just finalized its guidance for the industry in December. For a long time it was just a draft guidance, but now it's final and I found it to be quite helpful."

"There's this major need to understand the patient population, and I see this as threefold. So, understanding country-specific prevalence, the quality of the existing natural history data, and the different phenotypes to target the correct patient population. And there are major pitfalls here if you rush through the process. So you can grossly overestimate patient population if you're using averages instead of really looking into very specific data. So this can lead to slower recruitment and longer timelines once you actually start your study."

#AstellasPharma #GeneTherapy #RareDiseases #Allogeneic #ClinicalTrials #CNS #NeuromuscularDiseases

astellas.com/us/

Listen to the podcast here

Ha Tran, Medical Head, Cell and Gene Therapy at Astellas Pharma is developing gene therapy approaches to fight neuromuscular diseases, central nervous system disorders, and ophthalmology conditions. There is strong evidence that this approach can be a way to treat and possibly cure rare diseases. Ha explains the challenges of running gene therapy trials for rare diseases and the unique patient journey required to run a successful trial.

Ha explains, "Currently, at Astellas, our platform is AAV gene therapy, which is a replacement. Additionally, in our early pipeline, we are looking at both gene therapy replacement and vectorized RNA knockdown. We also have a cell therapy division, which I also cover. For that, we're looking at in vivo cell therapy."

"Honestly speaking, gene and cell therapy trials have their nuances since they are often a single infusion or single injection. So, the preclinical data packages and long-term follow-up plans differ from standard drug development. But the biggest nuances actually for clinical trial design are in rare diseases. The FDA just finalized its guidance for the industry in December. For a long time it was just a draft guidance, but now it's final and I found it to be quite helpful."

"There's this major need to understand the patient population, and I see this as threefold. So, understanding country-specific prevalence, the quality of the existing natural history data, and the different phenotypes to target the correct patient population. And there are major pitfalls here if you rush through the process. So you can grossly overestimate patient population if you're using averages instead of really looking into very specific data. So this can lead to slower recruitment and longer timelines once you actually start your study."

#AstellasPharma #GeneTherapy #RareDiseases #Allogeneic #ClinicalTrials #CNS #NeuromuscularDiseases

astellas.com/us/

Download the transcript here

Hari Mix, Founder and CEO of Calorify, is a former elite endurance athlete and aims to bring to market an accurate, affordable measurement of calorie intake and expenditure to address metabolic health. Measuring metabolism has generally been inaccessible due to the complexity and cost of traditional testing. With an in-home kit, the mission is to help those looking to improve their energy levels, lose weight, athletes, and medical professionals working with patients with metabolic-related health challenges.

Hari elaborates, "Our mission is pretty simple, and it's also pretty complicated. Simply put, our mission is to measure the world's metabolism. We believe that the world is facing a huge set of problems related to metabolic health, and nobody is measuring the key component of that, which is how many calories people are eating and burning, in an accurate way in a real-world setting. Our goal is to bring those measurements to the world, empower individuals to understand and improve their bodies and empower institutions to find solutions to metabolic problems and diseases."

"The name of the approach is called doubly labeled water. It's been around for many decades. It was first invented in 1949. It was first done on mice in 1955, and it was first done on humans in 1982. For decades, it's long been known to be the gold standard method of measuring how many calories people eat and burn in a real-world setting. However, it's been very, very expensive, very slow, cumbersome, and so it just hasn't been accessible to regular folks. Only about 15,000 people have ever been measured; that's about one person globally per day since the technology was launched in 1982. And so we've solved a suite of problems to bring this test to the world, make it a lot faster so that people can use their results, and make it a lot cheaper so that it's possible for them to afford this testing."

"Let's take an NBA team that we're working with. We find guys on the same team with the same lean body mass and the same job description, and yet one person is burning calories twice as fast as their teammate, and you couldn't tell by looking at them. It's extraordinary the degree to which you could put the same amount of food in your body and have it be completely different from the person standing next to you."

#Calorify #MetabolicTesting #Metabolism #Calories #Diets #EnergyAvailability

Calorify.com

Listen to the podcast here

Hari Mix, Founder and CEO of Calorify, is a former elite endurance athlete and aims to bring to market an accurate, affordable measurement of calorie intake and expenditure to address metabolic health. Measuring metabolism has generally been inaccessible due to the complexity and cost of traditional testing. With an in-home kit, the mission is to help those looking to improve their energy levels, lose weight, athletes, and medical professionals working with patients with metabolic-related health challenges.

Hari elaborates, "Our mission is pretty simple, and it's also pretty complicated. Simply put, our mission is to measure the world's metabolism. We believe that the world is facing a huge set of problems related to metabolic health, and nobody is measuring the key component of that, which is how many calories people are eating and burning, in an accurate way in a real-world setting. Our goal is to bring those measurements to the world, empower individuals to understand and improve their bodies and empower institutions to find solutions to metabolic problems and diseases."

"The name of the approach is called doubly labeled water. It's been around for many decades. It was first invented in 1949. It was first done on mice in 1955, and it was first done on humans in 1982. For decades, it's long been known to be the gold standard method of measuring how many calories people eat and burn in a real-world setting. However, it's been very, very expensive, very slow, cumbersome, and so it just hasn't been accessible to regular folks. Only about 15,000 people have ever been measured; that's about one person globally per day since the technology was launched in 1982. And so we've solved a suite of problems to bring this test to the world, make it a lot faster so that people can use their results, and make it a lot cheaper so that it's possible for them to afford this testing."

"Let's take an NBA team that we're working with. We find guys on the same team with the same lean body mass and the same job description, and yet one person is burning calories twice as fast as their teammate, and you couldn't tell by looking at them. It's extraordinary the degree to which you could put the same amount of food in your body and have it be completely different from the person standing next to you."

#Calorify #MetabolicTesting #Metabolism #Calories #Diets #EnergyAvailability

Calorify.com

Download the transcript here